欢迎访问厦门大学生命科学学院官方网站

邓贤明教授博导

发布时间:2016-04-16来源:点击数:23715

 

邓贤明 DENG Xianming, Ph.D.

邓贤明教授博导授,博士生导师                      

Chemical Biology and Medicinal Chemistry Group

课题组组长

  : +86-592-2184180

  : +86-592-2181722

E-mail:xmdeng@xmu.edu.cn

Group web: http://121.192.179.196/lmpe/

 

2001年,厦门大学化学系化学专业,获理学学士学位;

2006年,中科院上海有机化学研究所有机化学专业,获理学博士学位;

2006年至2011年,哈佛医学院Dana-Farber癌症研究所,博士后研究;

201110月起,为厦门大学生命科学学院闽江学者特聘教授,微生物药物课题组学科带头人,入选中组部青年千人计划。

 

2001B.Sc., Xiamen University;

2006, Ph.D., Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences.

2006-2011, Research Fellow, Dana-Farber Cancer Institute, Harvard Medical School.

2011.10-, Principal Investigator of Chemical Biology and Medicinal Chemistry Group, School of Life Sciences, Xiamen University.

 

主要研究领域(Research Area

化学生物学和药物化学。在化学生物学方面,我们集中于设计并合成新颖的针对蛋白激酶(Protein Kinase)和表观遗传蛋白(Epigenetic Enzyme)的小分子抑制剂,并运用这些功能小分子为工具,发现和解决信号传导通路、神经生物学和癌症中的新问题。在药物化学方面,以化学生物学研究成果为基础,结合传统的药物化学手段(构效关系研究、药代动力学和毒理学研究)进一步优化小分子工具化合物,以期发展针对癌症等相关疾病的靶向治疗药物。

Our research is focused on two major areas: chemical biology and medicinal chemistry. At the interface of chemistry and biology, we use organic synthesis to create new chemical tools for studying biological problems in human health and disease. These functional small-molecule tools are applied to control and elucidate cellular signal transduction in  cancer, stem cell, and neural diseases. Second, we pursue established medicinal chemistry approaches including structure activity relationship (SAR) study and pharmacokinetics modification to optimize pre-clinical drug candidates. We're working to address the following general questions: a) How can we develop small-molecule modulators with selectivity towards desired targets such as protein kinases and epigenetic enzymes? b) How can we use discovered-small-molecule tools to dissect the  molecular signaling pathways? c) How can we develop the 'lead' of targeted-drug from the tool compound?  

 

图片

 

代表性论文(Selected publications(#Co-first authorship,*Corresponding author)

1.    Fan, F.; He, Z.; Kong, L. L.; Chen, Q.; Yuan, Q.; Zhang, S.; Ye, J.; Liu, H.; Sun, X.; Geng, J.; Yuan, L.; Hong, L.; Xiao, C.; Zhang, W.; Li, Y.; Wang, P.; Huang, L.; Wu, X.; Ji, Z.; Wu, Q.; Xia, N. S.; Gray, N. S.; Chen, L.; Yun, C. H.*; Deng, X.*; Zhou, D.* Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Science Translational Medicine 2016, 8, 352ra108.(Cover story, Highlighted by Nature Reviews Gastroenterology & Hepatology) .

2.    Jiang, J.; Gui, F.; He, Z.; Li, L.; Li, Y.; Li, S.; Wu, X.; Deng, Z.; Sun, X.; Huang, X.; Huang, W.; Han, S.; Zhang, T.; Wang, Z.; Jiao, B.; Song, S.; Wang, H.-R.; Chen, L.; Zhou, D.; Liu, Q.; Ren, R.*; Zhang, J.*; Deng, X.* Targeting BRK-positive breast cancers with small molecule kinase inhibitors. Cancer Research. 2016, DOI: 10.1158/00085472.CAN161038 (Highlighted by BioWorldTM).

3.    Huang, X.; Huang, W.; Li, L.; Sun, X.; Song, S.; Xu, Q.; Zhang, L.; Wei, B. G.; Deng, X.* Structure Determinants of Lagunamide A for Anticancer Activity and Its Molecular Mechanism of Mitochondrial Apoptosis. Mol. Pharm. 2016, DOI: 10.1021/acs.molpharmaceut.6b00564.

4.    Wang, Y.; Qi, S.; Zhan, Y.; Zhang, N.; Wu, A.; Gui, F.; Guo, K.; Yang, Y.; Hu, Z.; Zheng, Z.; Song, S.; Xu, Q.; Shen, Y.*; Deng, X.* Aspertetranones A-D, Meroterpenoids from the Marine Algal-associated Fungus Aspergillus sp. J. Nat. Prod. 2015, 78, 2405-10.

5.    Li, D.; Huang, Y.; Song, S.; Xue, C.; Wu, Y.*; Deng, X.*Kibdelosporangium lantanae sp. nov., isolated from the rhizosphere soil of an ornamental plant, Lantana camara L. Int. J. Syst. Evol. Microbiol.2015,65, 2581-5.

6.    Li, D.; Song, J. Huang, Y.; Song, S.; Wu, Y.*; Deng, X.*Kribbella mirabilis sp. nov., isolated from rhizosphere soil of a herbaceous plant, Mirabilis jalapa L. Int. J. Syst. Evol. Microbiol.2015,65, 3143-7.

7.    Tang, Q.; Guo, K.; Li, X.-Y.; Zheng, X.-Y.; Kong, X.-J.; Zheng, Z.-H.; Xu, Q.-Y. *; Deng, X.* Three New Asperentin Derivatives from the Algicolous Fungus Aspergillus sp. F00785. Marine Drugs 2014, 12, 5993-6002.

8.    Guo, K.; Fang, T.; Wang, J.; Wu, A.-a.; Wang, Y.; Jiang, J.; Wu, X.; Song, S.; Su, W.; Xu, Q.*; Deng, X.* Two new spirooxindole alkaloids from rhizosphere strain Streptomyces sp. xzqh-9. Bioorg. Med. Chem. Lett.2014, 24, 4995-4998.

9.    Deng, X.*; Gray, N. S.* (WO2011141756) pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation. Expert Opin. Ther. Pat.2012, 22, 709-713.

10.  Deng, X. #; Dzamko, N. #; Prescott, A.; Davies, P.; Liu, Q.; Yang, Q.; Lee, J. D.; Patricelli, M. P.; Nomanbhoy, T. K.; Alessi, D. R.; Gray, N. S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chemical. Biology.2011, 7, 203-5.

11.  Yang, Q.#; Deng, X#; Lu, B. #; Cameron, M.; Fearns, C.; Patricelli, M. P.; Yates, J. R., 3rd; Gray, N. S.; Lee, J. D. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell2010,18, 258-67.

12.  Deng, X. #; Okram, B.#; Ding, Q. #; Zhang, J. #; Choi, Y.; Adrian, F. J.; Wojciechowski, A.; Zhang, G.; Che, J.; Bursulaya, B.; Cowan-Jacob, S. W.; Rummel, G.; Sim, T.; Gray, N. S. Expanding the diversity of allosteric bcr-abl inhibitors. J. Med. Chem.2010, 53, 6934-46.

 

已申请的专利

1.Gray, N. S.; Zhang, J.; Okram, B.; Deng, X.; Chang, J.; Wojciechowski, A. PCT Int.   

      Appl. WO2009073153(US granted). .

2.Gray, N. S.; Deng, X.; Kwiatkowski, N. P. PCT Int. Appl. WO2010080712.

3.Gray, N. S.; Zhou, W.; Deng, X. PCT Int. Appl. WO2011115725.